Gilead Sciences Inc. Chief Executive Officer Daniel O’Day, who took the reins in March, said one of his top priorities is bolstering the biotechnology giant’s drug pipeline.
Gilead’s blockbuster hepatitis C franchise turned the company into a pharmaceutical giant, but sales have slipped from their peak. O’Day, a 54-year-old former Roche Holding AG veteran, needs to find a way to reinvigorate the company.
“I was drawn by the potential I saw to build on a legacy,” O’Day said Thursday on his first quarterly conference call with analysts, after Gilead reported earnings that beat the highest estimates.
Adjusted earnings per share ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.